U.S. markets close in 3 hours

Cyclo Therapeutics, Inc. (CTDH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1010-0.0020 (-1.94%)
As of 12:41PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1030
Open0.1030
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1010 - 0.1060
52 Week Range0.0800 - 0.4400
Volume54,612
Avg. Volume192,389
Market Cap17.168M
Beta (5Y Monthly)-0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA

    Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC) today announced that the company received notification from the US FDA that enrollment can proceed for its Phase 3 global pivotal clinical trial, "A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1".

  • Business Wire

    Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

    Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the Niemann-Pick UK (NPUK) 11th Interactive Workshop on Niemann-Pick Diseases and the 27th Annual NPUK Family Conference. The conference brings together patients, families, caregivers, scientists, and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support. The conference will take place virtually from September 25 to 27, 2020.

  • Business Wire

    Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

    Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that 3 additional patients have completed the 48-week Phase I/II study. Results show encouraging trends in efficacy, consistent with findings of the first four patients who completed the study, as reported in the company’s Interim Analysis in May 2020.